Clopidogrel desensitization protocol for the treatment of thienopyridine hypersensitivity

Critical Pathways in Cardiology

Volumn 6, Issue 1, 2007, Pages 26-29

  Walker, Nicholas E ^a   Fasano, Mary B ^a   Hobbs, Ryan A ^b   Horwitz, Phillip A ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Clopidogrel; Desensitization; Hypersensitivity; Percutaneous coronary intervention

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPHENHYDRAMINE; GLUCAGON; METHYLPREDNISOLONE; RANITIDINE; SALBUTAMOL; STEROID; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANAPHYLAXIS; ARTICLE; CARDIOLOGY; CLINICAL PROTOCOL; CORONARY STENT; DESENSITIZATION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SENSITIZATION; FLUSHING; HEALTH SERVICE; HUMAN; MEDICAL SPECIALIST; OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN EXFOLIATION; URTICARIA;

ALGORITHMS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL PROTOCOLS; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; EXANTHEMA; HUMANS; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; STENTS; TICLOPIDINE;

EID: 33947119551     PISSN: 1535282X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hpc.0000256476.82317.77     Document Type: Article

References (22)

1. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999;100:1667-1672.
2. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348:1329-1339.
3. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
4. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.
5. Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
6. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
7. Camara MG, Almeda FQ. Clopidogrel (Plavix) desensitization: a case series. Catheter Cardiovasc Interv. 2005;65:525-527.
8. Fischer TC, Worm M, Groneberg DA. Clopidogrel-associated angioedema. Am J Med. 2003;114:77-78.
9. Gowda RM, Misra D, Khan IA. Hypersensitivity skin rash: an adverse drug reaction to clopidogrel loading dose. Int J Cardiol. 2004;95:333.
10. Khambekar SK, Kovac J, Gershlick AH. Clopidogrel induced urticarial rash in a patient with left main stem percutaneous coronary intervention: management issues. Heart. 2004;90:e14.
11. FDA MedWatch. October 2004. Available at www.fda.gov/medwatch/safety/ 2004/oct04. htm. Accessed August 1, 2005.
12. Sarrot-Reynauld F, Bouillet L, Bourrain JL. Severe hypersensitivity associated with clopidogrel. Ann Intern Med. 2001;135:305-306.
13. Vigo PG, MacDowell AL, Wedner HJ. Successful desensitization with clopidogrel after a positive skin test. Ann Allergy Asthma Immunol. 2005;94:132.
14. Walker NE, Fasano MB, Horwitz PA. Desensitization for the management of clopidogrel hypersensitivity: initial clinical experience. J Invasive Cardiol. 2006;18:341-344.
15. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1:1215-1220.
16. Gill S, Majumdar S, Brown NE, et al. Ticlopidine-associated pancytopenia: implications of an acetylsalicylic acid alternative. Can J Cardiol. 1997;13:909-913.
17. Page Y, Tardy B, Zeni F, et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet. 1991;337:774-776.
18. Steinhubl SR, Tan WA, Foody JM, et al. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. JAMA. 1999;281:806-810.
19. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2:15-28.
20. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med. 1998;129:394-405.
21. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med. 1998;339:1665-1671.
22. Lang DM. Anaphylactoid and anaphylactic reactions. Hazards of beta-blockers. Drug Saf. 1995;12:299-304.